Schultze-Mosgau MH

No ORCID on file · 5 papers in corpus
rct 2020
Journal of clinical pharmacology ·doi:10.1002/jcph.1608

This open label, parallel-group study investigated the pharmacokinetics and safety of a single oral 2-mg dose of the novel selective progesterone receptor modulator vilaprisan in participants with impaired renal function compared with age, …

nonrandomized-trial 2020
Clinical pharmacology in drug development ·doi:10.1002/cpdd.851

Vilaprisan is a novel selective progesterone receptor modulator for the long-term treatment of uterine fibroids and endometriosis. This study investigated the pharmacokinetics, safety, and tolerability of vilaprisan in healthy Chinese postm…

other 2018
ChemMedChem ·doi:10.1002/cmdc.201800487

Progesterone plays an important role in the female reproductive system. However, there is also evidence that gynecologic disorders/diseases such as uterine fibroids and endometriosis are progesterone-dependent. Steroidal and non-steroidal s…

rct 2016
Journal of clinical pharmacology ·doi:10.1002/jcph.846

Pharmacokinetics (PK) of anastrozole (ATZ) and levonorgestrel (LNG) released from an intravaginal ring (IVR) intended to treat endometriosis symptoms were characterized, and the exposure-response relationship focusing on the development of …

rct 2016
Human Reproduction ·doi:10.1093/humrep/dew145

STUDY QUESTION: What are suitable doses of the aromatase inhibitor anastrozole (ATZ) and the progestin levonorgestrel (LNG), when delivered to the systemic circulation by an intravaginal ring (IVR), for further clinical development as a pot…